Physician profile
Murphy Allen
NPI 1770544983
$1,631.94
in general payments reported to CMS, 2019-2025
23 companies · $914 in 2025
The $914 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $718 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.69 | 2024-2025 | |
| Amgen INC. | $175.92 | 2024-2025 | Repatha, Otezla, Otezla |
| Vanda Pharmaceuticals INC. | $120.59 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $110.79 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astrazeneca Pharmaceuticals Lp | $109.93 | 2024-2025 | Breztri |
| Exact Sciences Corporation | $63.50 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $62.82 | 2024-2025 | |
| Corium, LLC | $53.37 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $53.05 | 2025 | Qelbree |
| Indivior INC. | $47.91 | 2024-2025 | Perseris, Sublocade |
| Tris Pharma INC | $46.65 | 2025 | Dyanavel Xr |
| Mayne Pharma Commercial LLC | $46.41 | 2025 | |
| Lilly USA, LLC | $39.26 | 2024-2025 | Mounjaro, Zepbound |
| Almatica Pharma LLC | $38.88 | 2024-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $26.77 | 2025 | Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $26.06 | 2024 | Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $25.58 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.99 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $20.56 | 2024 | Keveyis |
| Abbott Laboratories | $20.44 | 2025 | Eterna |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $19.05 | 2025 | |
| Merck Sharp & Dohme LLC | $13.52 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murphy Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.